Roche Secures Dicerna RNAi Deal For Hepatitis B
Roche Pays $200m Up Front For DCR-HBVS Candidate
Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.
You may also be interested in...
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
At EASL 2020, four partnerships updated RNA-interference or antisense efforts to reduce hep B surface antigen, believed to lead to functional cure of the virus. One analyst sees J&J/Arrowhead as the early leader.